Abbreviations used in this paper:AGA (American Gastroenterological Association), GRADE (Grading of Recommendations Assessment, Development and Evaluation)
- American Gastroenterological Association institute technical review on the medical management of microscopic colitis.Gastroenterology. 2016; 150: 247-274
AGA Institute clinical practice guideline development process. http://www.gastro.org/guidelines/guidelines-policies.
- Clinical practice guidelines we can trust.Institute of Medicine; The National Academies Press, Washington, DC2011
- The AGA Institute process for developing clinical practice guidelines part one: grading the evidence.Clin Gastroenterol Hepatol. 2013; 11: 329-332
- Treatment of refractory microscopic colitis with azathioprine and 6-mercaptopurine.Gastroenterology. 2001; 120: 1483-1484
- Efficacy of anti-TNF therapies in refractory severe microscopic colitis.J Crohns Colitis. 2011; 5: 612-618
- Adalimumab in budesonide and methotrexate refractory collagenous colitis.Scand J Gastroenterol. 2012; 47: 59-63
- Successful use of infliximab in the treatment of corticosteroid dependent collagenous colitis.Am J Gastroenterol. 2013; 108: 857-858
- Azathioprine and mercaptopurine in the management of patients with chronic, active microscopic colitis.Aliment Pharmacol Ther. 2013; 37: 795-798
This article has an accompanying continuing medical education activity on page e17. Learning Objective: Upon completion of this test, successful learners will be able to: (1) learn first-line treatment for the induction of remission in microscopic colitis; (2) identify the expected clinical benefits and adverse effects of induction therapy for microscopic colitis; (3) understand the indications for and dosing of maintenance therapy for microscopic colitis; (4) consider medications that may precipitate microscopic colitis especially in those who are refractory to medical therapy; and (5) become familiar with treatment strategies for microscopic colitis refractory to first-line therapy.
Reprint requests Address requests for reprints to: Chair, Clinical Guidelines Committee, AGA National Office, 4930 Del Ray Avenue, Bethesda, Maryland 20814. e-mail: [email protected] ; telephone: (301) 941-2618.
Conflicts of interest All guideline panel members were required to complete disclosure statements. These statements are maintained at the American Gastroenterological Association Institute headquarters in Bethesda, Maryland, and pertinent disclosures are published with the report.